国药集团一致药业股份有限公司 2014 年第三季度报告全文
China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2014
October 2014
1
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements, misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third Quarter Report of the Company in
person.
Yan Zhigang, person in charge of the Company, head of the accounting works Wei Pingxiao and Zhou Feifei,
accounting body principals (accountant in charge) hereby confirm that the Financial Report of the Third Quarterly
Report is authentic, accurate and complete.
2
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Section II. Main accounting data and changes of shareholders
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets(RMB) 12,966,919,771.22 11,057,896,941.31 17.26%
Net assets attributable to
shareholders of listed company 4,567,637,308.84 2,244,757,658.03 103.48%
(RMB)
Increase/decrease in
Increase/decrease in
Year-begin to end of comparison with
Current period comparison with same
the Period year-begin to
period of last year
Period-end of last year
Operating revenue (RMB) 6,281,963,971.53 13.30% 17,894,606,405.81 14.15%
Net profit attributable to
shareholders of the listed company 158,726,925.31 16.81% 505,688,779.43 27.48%
(RMB)
Net profit attributable to
shareholders of the listed company
151,673,633.73 17.05% 475,947,603.34 22.11%
after deducting non-recurring
gains and losses(RMB)
Net cash flow arising from
-- -- -589,344,250.11 -340.73%
operating activities(RMB)
Basic earnings per share
0.438 -7.20% 1.497 8.71%
(RMB/Share)
Diluted earnings per share
0.438 -7.20% 1.497 8.71%
(RMB/Share)
Weighted average ROE 3.54% -3.08% 13.49% -6.90%
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Amount from year-begin to
Item Note
end of the Period
Gains/losses from the disposal of non-current asset (including the 412,515.69
3
国药集团一致药业股份有限公司 2014 年第三季度报告全文
write-off that accrued for impairment of assets)
The enterprise supporting fund
RMB 7.97 million allocated from
Nanning Economic and
Technological Development
Zone, the deferred income
recognized due to compensation
for removal project was
amortized RMB 2.02 million in
the Period; special subsidy RMB
Governmental subsidy reckoned into current gains/losses (not 2.28 million from Shenzhen
including the subsidy enjoyed in quota or ration according to High-tech industries; patent
20,223,451.02
national standards, which are closely relevant to enterprise’s subsidy RMB 1.66 million from
business) Development & Finance Bureau
of Longhua New District of
Shenzhen; the deferred income
recognized for special supporting
fund of new-type Cephalosporin
project lab was amortized RMB
1.1 million in the Period;
cultivation subsidy of strategy
emerging industry brand RMB 1
million etc.
Reversal of impairment reserve for account receivable with
2,882,594.76
separate impairment testing
Mainly refers to the RMB 11.86
million compensation of Chebei
Other non-operating income and expenditure except for the
14,690,120.52 lawsuit that accrued last year was
aforementioned items
released according to the latest
lawsuit results
Less: impact on income tax 8,439,384.53
Impact on minority shareholders’ equity (post-tax) 28,121.37
Total 29,741,176.09 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.
4
国药集团一致药业股份有限公司 2014 年第三季度报告全文
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Statement of the total common shareholders and shares-held of top ten common
shareholders at end of the Period
In Share
Total common shareholders at
10,970
period-end
Shares-held of top ten common shareholders
Amount of Number of share pledged/frozen
Nature of Proportion of Amount of shares
Shareholders restricted shares
shareholder shares held held State of share Amount
held
Domestic non
Sinopharm Group
state-owned 51.00% 184,942,291 74,482,543
Co., Ltd.
corporate
National Council Domestic non
for Social Security state-owned 2.51% 9,110,015
Fund – 116 corporate
National Council Domestic non
for Social Security state-owned 2.01% 7,298,555
Fund – 106 corporate
HTHK/CMG
FSGUFP-CMG
Overseas
FIRST STATE 1.94% 7,032,720
corporate
CHINA GROWTH
FD
BOC-Harvest
Domestic non
research selected
state-owned 1.26% 4,551,404
stock securities
corporate
investment fund
ICBC—Harvest Domestic non
Strategy Growth state-owned 1.23% 4,451,985
Mix Stock Fund corporate
CCB – China AMC
Domestic non
Advantage Growth
state-owned 1.10% 4,005,289
Stock Investment
corporate
Fund
VALUE
Overseas
PARTNERS 1.05% 3,791,661
corporate
CLASSIC FUND
5
国药集团一致药业股份有限公司 2014 年第三季度报告全文
ICBC—Harvest
Domestic non
Theme New Power
state-owned 1.01% 3,653,161
stock securities
corporate
investment fund
Fenghe Value Domestic non
Securities state-owned 0.94% 3,393,162
Investment Funds corporate
Particular about top ten common shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict common shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
National Council for Social Security RMB ordinary
9,110,015 9,110,015
Fund – 116 shares
National Council for Social Security RMB ordinary
7,298,555 7,298,555
Fund – 106 shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
BOC-Harvest research selected stock RMB ordinary
4,551,404 4,551,404
securities investment fund shares
ICBC—Harvest Strategy Growth Mix RMB ordinary
4,451,985 4,451,985
Stock Fund shares
CCB – China AMC Advantage RMB ordinary
4,005,289 4,005,289
Growth Stock Investment Fund shares
Domestically
VALUE PARTNERS CLASSIC
3,791,661 listed foreign 3,791,661
FUND
shares
ICBC—Harvest Theme New Power RMB ordinary
3,653,161 3,653,161
stock securities investment fund shares
Fenghe Value Securities Investment RMB ordinary
3,393,162 3,393,162
Funds shares
BOC-Harvest research selected stock securities investment fund, BOC-Harvest research
selected stock securities investment fund and ICBC—Harvest Theme New Power stock
Explanation on associated securities investment fund shares the same administrator as Harvest Fund Management Co.,
relationship among the aforesaid Ltd.; VALUE PARTNERS CLASSIC FUND, one of the top ten shareholders, is one of the
shareholders VALUE PARTNERS; it is unknown that there exists no associated relationship or belongs to
the consistent actionist among the other tradable shareholders regulated by the Management
Measure of Information Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
6
国药集团一致药业股份有限公司 2014 年第三季度报告全文
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings in Period-end
□Applicable √Not applicable
7
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
I. Impacts of implementation of new Accounting Standard for Business Enterprises No.9 – Employee Compensation on
financial status and operation results of the Company
1. In light of the revised Accounting Standard for Business Enterprises No.9 – Employee Compensation, being assessed, apart from
the inner retired spending plan represented in financial statement of the Company currently, the after-service allowance and medical
benefit given to service workers and retirees are on the “defined benefit plans” domain of revised Accounting Standard for Business
Enterprises No.9 – Employee Compensation, therefore, payment plan for such part shall be measure accurately, relevant obligation
shall be recognized and reckoned into current gains/losses during the period of an employee providing services to the enterprise. The
Company adjusted the above mentioned after-service allowance for year of 2014 (listed with RMB/CNY) subject to the requirement
of the standards:
(1) Retroactive treatment on financial statement dated 1 January 2014: increasing RMB 60.42 million in payroll payable (the
long-term employee benefits listed in “other non-current liability” in line with the new standards); reducing RMB 1.48 million in
other comprehensive income; reducing retained profit RMB 45.98 million; minority interest decreased RMB 500,000 and increasing
RMB 12.45 million in deferred income tax assets.
(2) Adjustment for gains/losses of financial statement of 3Q for year of 2014: increase amount of RMB 1.52 million in financial
expenses, increase amount of RMB 1.26 million in management expenses, decreasing RMB 530,000 for income tax expense and
decreasing RMB 4,000 for minority interest income.
（3）According to the “Article 31: information disclosed in comparative financial statement before the Standards come into play are
inconsistent with the requirement of the Standards, enterprise do not need to adjusted in accordance with the provisions of this
Standards” in revised Accounting Standard for Business Enterprises No.9 – Employee Compensation, the financial statement of 2013
and 3Q of 2013 no need of adjustment therefore.
2. Material actuarial assumption that defined benefit plans obligation depends on
Data of defined benefit plans calculated based on the follow assumptions: discount rate 4.25%, wages growth rate 2.5%, pension
growth rate 5% and the mortality rate refers to the average estimate life for people in mainland China.
3. Influenced by change of Employee Compensation
Payroll payable dated 1 January 2014 Interest attributable to shareholder of parent company
dated 1 January 2014
60,419,000.00 -47,466,075.00
Enterprise China National Accord Medicines Corporation
Ltd.
Corporate Yan Zhigang
Dated 25 October 2014
8
国药集团一致药业股份有限公司 2014 年第三季度报告全文
II. Particular about major changes from items of main accounting statements and financial indexes as well as reasons
1. Account paid in advance: has 53.82% rate of increase, mainly because account for merchandise purchase paid in advance
increased in the Period;
2. Other current assets: has 115.80% rate of increase, mainly due to the VAT retained increased in Period;
3. Construction in progress: has 95.49% rate of increase, mainly because investment for Pingshan Base project etc. increased in
Period;
4. Deferred income tax assets: has 39.62% rate of increase, mainly due to the temporary differences of income tax that arising from
payroll payable adjustment and withholding selling expenses etc. in line with requirement of Accounting Standard for Business
Enterprises No.9 – Employee Compensation in Period;
5. Other non-current assets: has 43.31% rate of increase, mainly because investment for Pingshan Base project etc. increased, amount
paid in advance for construction and equipment increased over that of period-begin;
6. Short-term loans: has -46.25% rate of increase, mainly because the capital increment of targeted placement received, and part of
short-term loans are paid in the Period;
7. Other current liability: has -100% rate of increase, mainly because the lawsuit compensation for Chebei project in final decision
decreased;
8. Long-term loans: has 100% rate of increase, mainly because long-term loans from China National Pharmaceutical Finance
Company and outer banks increased in Period;
9. Special accounts payable: has -69.98% rate of increase, mainly because the enterprise technology center project supporting by
government special subsidy is completed in the Period, the original amount reckoned in special account payable is transfer into
capital reserve;
10. Other non-current liability: has 34.76% rate of increase, mainly because in line with new Accounting Standard for Business
Enterprises No.9 – Employee Compensation, long-term payable employee benefits are increased in Period;
11. Capital reserve: has 32313.5% rate of increase, mainly due to the share premium arising from targeted placement in the Period
while there was no such business occurred at end of last year;
12. Other comprehensive income(Balance sheet and profit statement): has -100% rate of increase, mainly due to the adjustment on
changes in actuarial loss in line with the new Accounting Standard for Business Enterprises No.9 – Employee Compensation in
Period;
13. Losses of devaluation of asset: has -49.77% rate of increase, mainly because accrual for bad debt and inventory falling price
reserves declined y-o-y in the Period;
14. Non-operating expense: has -93.09% rate of increase, mainly because lawsuit compensation for Chebei project was accrual at
same period of last year while no such business occurred in the Period;
15. Losses from disposal of non-current assets: has 78.49% rate of increase,, mainly because losses from disposal of fix assets in the
Period increased y-o-y;
16. Other cash received with operation activities concerned: has 41.07% rate of increase, mainly because government subsidy
obtained in the Period increased y-o-y;
17. Net cash flow arising from operating activities: has -340.73% rate of increase, mainly because payment for procurement and vary
taxes expenses paid in the Period increased y-o-y;
18. Net cash received from disposal of fixed assets, intangible assets and other long-term assets: decreased RMB 1.77 million on a
y-o-y basis with -58.50% rate growths, mainly because income from disposal of fixed assets declined y-o-y in the Period;
19. Cash paid for purchasing fixed assets, intangible assets and other long-term assets: has 222.78% rate of increase, mainly because
investments for Pingshan Base project etc. increased in Period;
20. Net cash paid for obtaining subsidiary and other operation units: has 983.61% rate of increase, mainly because the amounts of
9
国药集团一致药业股份有限公司 2014 年第三季度报告全文
equity are paid for enterprise acquisition in the Period;
21. Net cash flow arising from investing activities: has -393.86% rate of increase, mainly because investments for Pingshan Base
project etc. increased in Period;
22. Cash received from absorbing investment: has 100% rate of increase, mainly because the capital increment of targeted placement
received in the Period while no such business occurred at same period of last year;
23. Cash received from loans: has -70.88% rate of increase, mainly because loans from outside decreased for implementation of
targeted placement in the Period;
24. Other cash received with financing activities concerned: has -91.96% rate of increase, mainly because entrust loans received in
the Period decreased on a y-o-y basis;
25. Cash paid for settling debts: has 66.67% rate of increase, mainly because parts of the loans are paid by the capital increment of
targeted placement received in the Period;
26. Other cash paid concerning financing activities: has -87.73% rate of increase, mainly because the supplying chain financing paid
in the Period decreased y-o-y;
27. Net cash flow arising from financing activities: has 392.39% rate of increase, mainly because the capital increment of targeted
placement received in the Period while no such business occurred at same period of last year;
28. Influence on cash and cash equivalents due to fluctuation in exchange rate: has 188.83% rate of increase, mainly because foreign
currency holding increased;
29. Net increase of cash and cash equivalents: has 69.18% rate of increase, mainly impact by the capital increment of targeted
placement received in the Period.
II. Progress and influence of the main events as well as solution analysis specification
√ Applicable □Not applicable
The Company has 11,481 stock odd lots (11,200 of A-shares and 281 B-shares) arising from implementation of interest distribution,
and the shares are record in specific account of Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. (“CSDC” for
short). In order to solved the stock odd lots left over by history, in line with the requirement from CSRC, the Company entered into
the agreement of Listed Companies Trust Sales of Odd Lots to Shenzhen Branch of China Securities Depository and Clearing Co.,
Ltd. in July 2014. And earns net income of RMB 552,750.15 from selling the A-share in August 2014 and HK$ 10,876.76 from
selling the B-share
III. Commitments made by the Company or shareholders holding above 5% shares of the
Company in reporting period or made in previous period and extending to reporting period
√ Applicable □Not applicable
Commit
Commitm
Commitments Accepter Contents ment Implementation
ent time
period
Share Merger
Reform
As a large pharmaceutical commercial enterprise whose
Commitments in
business involves pharmaceutical wholesale and retail, Long-ter Normally
report of Sinopharm 2005-06-2
Sinopharm Holding may overlap with the Company in m implement
acquisition or Holding 1
geographical segmentation during its future business effective
equity change
development. To avoid the potential peer competition brought
10
国药集团一致药业股份有限公司 2014 年第三季度报告全文
by such geographical overlap, Sinopharm Holding undertakes
that, upon the transfer of shares of Sinopharm Holding
Guangzhou it held to Accord Pharma, “1. it will not
newly-establish or broaden within Guangdong any business
operation that actually compete with that of Accord Pharma,
or set up any new subsidiaries or subordinate enterprises who
engage in such business. 2. it will enter into business
delineation with Accord Pharma and Sinopharm Holding
Guangzhou, thereby giving the three parties clear
geographical areas to carry out pharmaceutical wholesale and
retail businesses, so as to avoid potential peer competition.
Apart from above, Sinopharm Holding will no longer
newly-establish any enterprise that may compete with Accord
Pharma in the production and R&D of pharmaceutical
products.”
Commitments in
assets
reorganization
Sinopharm Holding has undertaken in the Letter of
Undertaking from Sinopharm Group Co. Ltd. on Avoiding
Peer Competition that, “I. the Company and the enterprises it
wholly-owns, controls or has de facto control over (excluding
Sinopharm Accord and its controlled enterprises, similarly
hereinafter) do not exist any business or operation that would
constitute substantive peer competition with Sinopharm
Accord and its controlled enterprises. II. the Company and Controlling
the enterprises it wholly-owns, controls or has de facto shareholder is
control over will not engage in, participate in or carry out in implement in
Guangdong and Guangxi any business or activities that would real earnest,
Commitments constitute substantive competition with the pharmaceutical Sinopharm
Long-ter
make in initial Sinopharm commercial businesses of Sinopharm Accord. III. the 2013-09-0 Accord will
m
public offering Holding Company and the enterprises it wholly-owns, controls or has 5 actively urged
effective
or re-financing de facto control over will not engage in, participate in or carry the controlling
out any business or activities that would constitute shareholder and
substantive competition with the pharmaceutical industrial actual controller
businesses of Sinopharm Accord. IV. the Company will not to fulfill
make use of its control over Sinopharm Accord to damage the commitments
legal interests of Sinopharm Accord and other shareholders
(especially minority shareholders). The Letter of Undertaking
takes effect since the date of issue and will remain effective
during the entire period when the Company has been the
controlling shareholder or connected party of Sinopharm
Accord. During the validity of the Undertaking, the Company
will indemnify in time Sinopharm Accord from any loss
11
国药集团一致药业股份有限公司 2014 年第三季度报告全文
which may arise out of the Company’s violation of the
Undertaking.”
Sinopharm Holding has undertaken in the Letter of
Undertaking from Sinopharm Group Co. Ltd. on
Standardization of the Connected Transactions with China
National Accord Medicines Corporation Ltd. that, “I. during
the period when the Company takes control over Sinopharm
Accord, the Company and the companies or enterprises it
directly or indirectly controls (hereinafter referred to as
“Connected Party”) will strictly standardize the connected
transactions with Sinopharm Accord and its controlled
enterprises. II. for those connected transactions beyond
avoidance or out of reasonable causes, the Company and
Connected Party will enter into standardized connected
transaction agreement with Sinopharm Accord according to
law. Sinopharm Accord will perform approval procedure
according to relevant laws, rules and regulations, other
standardization documents and its constitutional documents, Controlling
and fulfill its obligation to disclose information on connected shareholder is
transactions. III. for those connected transactions beyond implement in
avoidance or out of reasonable causes, the Company and real earnest,
Connected Party will determine the prices of connected Sinopharm
Long-ter
Sinopharm transactions based on the prices of same or similar 2013-09-0 Accord will
m
Holding transactions entered into by independent third parties of no 5 actively urged
effective
connection while following the principles of open, fair and the controlling
just to ensure the fairness. IV. when the board or shareholder and
shareholders’ meeting of Sinopharm Accord votes on the actual controller
relevant connected transactions involving the Company and to fulfill
other enterprises it controls, the Company will perform commitments
obligations including that necessary interested directors and
shareholders shall be abstained from voting according to
relevant regulations, and follow the legal procedures for
approval of connected transactions and fulfill its information
disclosure obligation. V. the Company guarantees to attend
shareholders’ meeting according to the constitutional
documents of Sinopharm Accord, exercise its corresponding
rights and assumed its corresponding obligations in an
equitable manner, not to take advantage of its standing as
controlling shareholder to seek unjust interests, or to use
connected transactions to illegally transfer capital or profit
out of Sinopharm Accord, or to prejudice the legal interests of
Sinopharm Accord and other shareholders (especially
minority shareholders). VI. the Letter of Undertaking takes
effect since the date of issue and will remain effective during
12
国药集团一致药业股份有限公司 2014 年第三季度报告全文
the entire period when the Company has been the controlling
shareholder or connected party of Sinopharm Accord. During
the validity of the Undertaking, the Company will indemnify
in time Sinopharm Accord from any loss that may arise out of
the Company’s violation of the Undertaking.”
”Sinopharm Group has undertaken in the Letter of
Undertaking from China National Pharmaceutical Group
Corporation on Avoiding the Peer Competition with China
National Accord Medicines Corporation Ltd. that, “I. in the
coming five years, Sinopharm Group intends to take
appropriate measures including replacement or acquisition of
assets or equity reorganization to solve the problem of peer
Actual
competition between Weiqida and Sinopharm Accord. II.
controller is
apart from the matters disclosed in the past and in the Letter
implement in
of Undertaking, the Company and the enterprises it
real earnest,
wholly-owns, controls or has de facto control over (excluding
Sinopharm
Sinopharm Accord and its controlled enterprises, similarly Long-ter
Sinopharm 2013-10-1 Accord will
hereinafter) do not directly engage in, participate in or carry m
Group 6 actively urged
out within the PRC any business or activities that would effective
the controlling
constitute substantive competition with the production and
shareholder and
operation of Sinopharm Accord. The relative undertakings in
actual controller
respect of avoiding peer competition given by the Company
to fulfill
in the past remain valid. III. the Company will not take
commitments
advantage of its control over Sinopharm Accord to damage
the legal interests of Sinopharm Accord and other
shareholders (especially minority shareholders). IV. the
Letter of Undertaking takes effect since the date of issue and
will remain effective during the entire period when the
Company has been the de facto controller or connected party
of Sinopharm Accord.”
Sinopharm Group has undertaken in the Letter of Actual
Undertaking from China National Pharmaceutical Group controller is
Corporation on Standardization of the Connected implement in
Transactions with China National Accord Medicines real earnest,
Corporation Ltd that, “I. during the period when the Sinopharm
Long-ter
Sinopharm Company takes control over Sinopharm Accord, the 2013-09-2 Accord will
m
Group Company and the companies or enterprises it directly or 2 actively urged
effective
indirectly controls (hereinafter referred to as “Connected the controlling
Party”) will strictly standardize the connected transactions shareholder and
with Sinopharm Accord and its controlled enterprises. II. for actual controller
those connected transactions beyond avoidance or out of to fulfill
reasonable causes, the Company and Connected Party will commitments
13
国药集团一致药业股份有限公司 2014 年第三季度报告全文
enter into standardized connected transaction agreement with
Sinopharm Accord according to law. Sinopharm Accord
will perform approval procedure according to relevant laws,
rules and regulations, other standardization documents and its
constitutional documents, and fulfill its obligation to disclose
information on connected transactions. III. for those
connected transactions beyond avoidance or out of reasonable
causes, the Company and Connected Party will determine the
prices of connected transactions based on the prices of same
or similar transactions entered into by independent third
parties of no connection while following the principles of
open, fair and just to ensure the fairness. IV. when the board
or shareholders’ meeting of Sinopharm Accord votes on the
relevant connected transactions involving the Company and
other enterprises it controls, the Company will perform
obligations including that necessary interested directors and
shareholders shall be abstained from voting according to
relevant regulations, and follow the legal procedures for
approval of connected transactions and fulfill its information
disclosure obligation. V. the Company guarantees not to take
advantage of its standing as actual controller to seek unjust
interests, or to use connected transactions to illegally transfer
capital or profit out of Sinopharm Accord, or to prejudice the
legal interests of Sinopharm Accord and other shareholders
(especially minority shareholders).”VI. the Letter of
Undertaking takes effect since the date of issue and will
remain effective during the entire period when the Company
has been the actual controller or connected party of
Sinopharm Accord.
Other
commitments to
minority
shareholders of
the Company
Completed on
Yes
time or not
IV. Estimation of operation performance for year of 2014
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the
warning of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
14
国药集团一致药业股份有限公司 2014 年第三季度报告全文
V. Particular about security investment
□ Applicable √ Not applicable
The Company had no security investment in Period.
VI. Particulars about derivatives investment
□ Applicable √ Not applicable
The Company had no derivatives investment in Period.
VII. Registration form of receiving research, communication and interview in the report
period
√ Applicable □Not applicable
Contents
Time Place Way Type Reception discussed and
material provided
China Merchants Securities, Haitong
Securities, CCB Principal Asset
Management, Huarong Securities,
Zhongdian Xinan Investment
Management Co., Ltd., Yuance
Investment Management Co., Ltd.,
EverBright Securities, Mingyuan
Investment, Dingfeng Asset, Qingxi
Assets Management Co., Ltd., Huashang
Visited the
Fund Management, Shanghai Daweide
Company and
Investment Co., Ltd., Anbang Asset,
knew the
Greenwoods Asset Management,
influence of
Shenzhen Jingshi Investment
Accord Pharm. Field medical reform
2014-02-18 Institution Management Co., Ltd., Goldstate
Bldg. research policy to the
securities, First Capital, Shangcheng
development of
Asset Management、Tianfeng Securities,
the industry. No
Shenzhen Branch of Dongguan Securities,
material
CPIC Asset Management, China Southern
provided.
Asset Management, Marco Polo Zhizhen
Assets Management Co., Ltd., China
Asset Management, Anhui Guofu
Industrial Investment Fund Management,
First State Cinda Fund
Management, ,Hongguan Assets Co., Ltd.,
Shanghai Qinyuan Investment
Management Co., Ltd., GF Securities,
Industrial Securities, Fortune SG Fund
15
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Management and Sinolink Securities
Visited the
Company and
knew the
influence of
Accord Pharm. Field Essence Fund, CITIC Securities, China medical reform
2014-04-18 Institution
Bldg. research AMC, China Merchants Securities policy to the
development of
the industry. No
material
provided.
Knew the
influence of
Telephone
Accord Pharm. medical reform
2014-06-18 communicat Institution Guotai Junan
Bldg. policy to the
ion
development of
the industry
16
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Section IV. Financial Statement
I. Financial statement
1. Consolidated Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Closing balance Opening balance
Current assets:
Monetary funds 1,087,659,463.49 1,113,562,211.65
Settlement provisions
Capital lent
Financial assets measured by fair
value and whose change is recorded in
current gains and losses
Notes receivable 649,048,074.59 739,061,141.72
Accounts receivable 7,037,372,146.44 5,675,658,506.78
Accounts paid in advance 99,011,553.85 64,367,040.17
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Interest receivable
Dividend receivable
Other receivables 38,200,356.25 29,620,899.71
Purchase restituted finance asset
Inventories 2,262,291,024.16 1,831,267,290.00
Divided into assets held ready for
sales
Non-current asset due within one
year
Other current assets 26,335,389.72 12,203,752.77
Total current assets 11,199,918,008.50 9,465,740,842.80
Non-current assets:
Granted loans and advances
17
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 143,928,732.53 135,341,010.52
Investment property 73,340,383.00 77,269,718.14
Fixed assets 729,600,608.45 766,741,590.63
Construction in progress 247,498,795.18 126,606,806.01
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 145,661,975.96 150,561,964.46
Expense on Research and
5,619,315.47 5,619,315.47
Development
Goodwill 85,228,833.15 85,228,833.15
Long-term expenses to be
39,427,915.45 35,985,621.47
apportioned
Deferred income tax asset 96,194,509.98 68,895,938.25
Other non-current asset 200,500,693.55 139,905,300.41
Total non-current asset 1,767,001,762.72 1,592,156,098.51
Total assets 12,966,919,771.22 11,057,896,941.31
Current liabilities:
Short-term loans 1,475,398,823.88 2,744,941,589.11
Loan from central bank
Absorbing deposit and interbank
deposit
Capital borrowed
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Notes payable 1,346,039,416.38 1,495,401,188.09
Accounts payable 4,419,977,857.73 3,436,936,497.16
Accounts received in advance 36,289,869.86 38,570,231.44
Selling financial asset of
repurchase
Commission charge and
commission payable
18
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Wage payable 124,895,136.30 159,466,364.12
Taxes payable 82,911,400.22 76,045,260.04
Interest payable 9,433,304.98 13,065,850.14
Dividend payable
Other accounts payable 452,713,640.30 496,102,247.39
Reinsurance payables
Insurance contract reserve
Security trading of agency
Security sales of agency
Divided into liability held ready
for sale
Non-current liabilities due within 1
5,500,000.00 7,800,000.00
year
Other current liabilities 22,040,000.00
Total current liabilities 7,953,159,449.65 8,490,369,227.49
Non-current liabilities:
Long-term loans 39,695,448.00
Bonds payable
Long-term account payable
Special accounts payable 1,287,000.00 4,287,000.00
Projected liabilities
Deferred income tax liabilities 24,636,960.01 24,644,887.76
Other non-current liabilities 299,120,851.51 221,958,761.49
Total non-current liabilities 364,740,259.52 250,890,649.25
Total liabilities 8,317,899,709.17 8,741,259,876.74
Owner’s equity (or shareholders’
equity):
Paid-in capital (or share capital) 362,631,943.00 288,149,400.00
Capital public reserve 1,863,885,959.19 5,750,338.57
Other comprehensive income -4,170,242.50
Less: Inventory shares
Reasonable reserve
Surplus public reserve 144,855,634.40 144,855,634.40
Provision of general risk
Retained profit 2,200,434,014.75 1,806,002,285.06
19
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Balance difference of foreign
currency translation
Total owner’s equity attributable to
4,567,637,308.84 2,244,757,658.03
parent company
Minority interests 81,382,753.21 71,879,406.54
Total owner’s equity(or shareholders’
4,649,020,062.05 2,316,637,064.57
equity)
Total liabilities and owner’s equity(or
12,966,919,771.22 11,057,896,941.31
shareholders’ equity)
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
2. Balance Sheet of parent company
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Balance at period-end Balance at period-begin
Current assets:
Monetary funds 390,896,290.66 218,342,947.03
Financial assets measured by fair
value and whose change is recorded in
current gains and losses
Notes receivable 12,496,638.64 34,964,767.24
Accounts receivable 549,131,561.76 427,376,566.55
Accounts paid in advance 1,262,866.59 35,982.02
Interest receivable 3,306,508.38 1,650,552.45
Dividend receivable
Other receivables 2,214,122,324.81 1,160,527,938.29
Inventories 180,581,777.55 172,165,830.98
Divided into assets held ready for
sales
Non-current asset due within one year
Other current assets 1,006,149.05 2,657,068.36
Total current assets 3,352,804,117.44 2,017,721,652.92
Non-current assets:
Finance asset available for sales
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 1,607,528,226.91 1,583,340,504.90
Investment real estate 5,709,750.83 7,060,731.46
20
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Fixed assets 17,245,504.15 20,722,267.75
Construction in progress 167,812,206.30 54,974,475.13
Engineering material
Disposal of fixed asset
Productive biological asset
Oil and gas asset
Intangible assets 37,274,229.43 37,966,282.04
Expense on Research and Development
Goodwill
Long-term expenses to be apportioned 5,957,706.57 6,787,267.98
Deferred income tax asset 5,854,779.36 2,941,603.89
Other non-current asset 88,194,138.32 29,152,556.06
Total non-current asset 1,935,576,541.87 1,742,945,689.21
Total assets 5,288,380,659.31 3,760,667,342.13
Current liabilities:
Short-term loans 196,500,000.00 1,079,500,000.00
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Notes payable 182,918,216.83 247,283,090.92
Accounts payable 443,102,059.27 318,141,136.49
Accounts received in advance 284,541.86 291,691.40
Wage payable 16,044,361.22 16,512,245.17
Taxes payable 11,263,666.92 1,509,173.93
Interest payable 54,117.26 1,834,864.78
Dividend payable
Other accounts payable 302,580,970.58 421,121,969.02
Divided into liability held ready
for sale
Non-current liabilities due within 1 year
Other current liabilities
Total current liabilities 1,152,747,933.94 2,086,194,171.71
Non-current liabilities:
Long-term loans 39,695,448.00
Bonds payable
21
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Long-term account payable
Special accounts payable 800,000.00 800,000.00
Projected liabilities
Deferred income tax liabilities 3,773,319.00 3,773,319.00
Other non-current liabilities 16,770,408.28
Total non-current liabilities 61,039,175.28 4,573,319.00
Total liabilities 1,213,787,109.22 2,090,767,490.71
Owner’s equity (or shareholders’
equity):
Paid-up capital (or share capital) 362,631,943.00 288,149,400.00
Capital public reserve 1,869,684,347.55 14,548,726.93
Other comprehensive income -305,250.00
Less: Inventory shares
Reasonable reserve
Surplus public reserve 144,855,634.40 144,855,634.40
General risk reserve
Retained profit 1,697,726,875.14 1,222,346,090.09
Balance difference of foreign currency
translation
Total owner’s equity(or shareholders’
4,074,593,550.09 1,669,899,851.42
equity)
Total liabilities and owner’s equity(or
5,288,380,659.31 3,760,667,342.13
shareholders’ equity)
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
3. Consolidated Profit Statement (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Total operating income 6,281,963,971.53 5,544,642,435.73
Including: Operating income 6,281,963,971.53 5,544,642,435.73
Interest income
Insurance gained
Commission charge and commission
income
6,100,229,470.64
II. Total operating cost 5,386,462,164.01
Including: Operating cost 5,833,268,381.58 5,101,666,921.65
22
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of compensation
Net amount of withdrawal of insurance
contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 9,386,944.76 9,640,431.13
Sales expenses 112,238,970.55 110,789,296.79
Administration expenses 113,782,559.26 120,244,653.35
Financial expenses 29,944,760.23 43,166,999.25
Losses of devaluation of asset 1,607,854.26 953,861.84
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed with
13,143,999.51 11,938,333.75
“-”)
Including: Investment income on
13,143,999.51 11,938,333.75
affiliated company and joint venture
Exchange income (Loss is listed with
“-”)
III. Operating profit (Loss is listed 194,878,500.40
170,118,605.47
with “-”)
Add: Non-operating income 8,528,482.74 7,140,905.91
Less: Non-operating expense 330,963.49 155,387.82
Including: Disposal loss of non-current
215,831.48 128,040.97
asset
IV. Total Profit (Loss is listed with
203,076,019.65 177,104,123.56
“-”)
Less: Income tax expense 40,074,573.40 37,642,385.77
V. Net profit (Net loss is listed with “-”) 163,001,446.25 139,461,737.79
Including: net profit realized before
consolidation by mergered party
Net profit attributable to owner’s of
158,726,925.31 135,890,437.07
parent company
Minority shareholders’ gains and losses 4,274,520.94 3,571,300.72
VI. Earnings per share -- --
i. Basic earnings per share 0.438 0.472
ii. Diluted earnings per share 0.438 0.472
VII. Other consolidated income
Inc: Other comprehensive items un-able
23
国药集团一致药业股份有限公司 2014 年第三季度报告全文
to re-classify as gains/losses in later
accounting period
Other comprehensive items able
to re-classify as gains/losses in later
accounting period while regulated
conditions are satisfy
VIII. Total comprehensive income 163,001,446.25 139,461,737.79
Total consolidated income attributable
158,726,925.31 135,890,437.07
to owners of parent company
Total consolidated income attributable
4,274,520.94 3,571,300.72
to minority shareholders
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
4. Profit Statement of parent company (this report period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Items Amount in this period Amount in last period
I. Operating income 734,321,077.76 677,759,418.03
Less: operating cost 705,436,495.45 646,491,560.76
Operating tax and extras 2,430,299.49 1,456,413.47
Sales expenses 12,365,596.47 14,384,558.76
Administration expenses 11,578,094.71 21,547,551.30
Financial expenses -30,454,474.94 131,996.79
Losses of devaluation of asset 116,740.12 -68,838.55
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed with
18,064,754.09 17,107,709.21
“-”)
Including: Investment income on
13,143,999.51 11,938,333.75
affiliated company and joint venture
II. Operating profit (Loss is listed
50,913,080.55 10,923,884.71
with “-”)
Add: Non-operating income 10,044.48 3,470,686.99
Less: Non-operating expense 0.00 2,000.00
Including: Disposal loss of non-current
asset
III. Total Profit (Loss is listed with
50,923,125.03 14,392,571.70
“-”)
Less: Income tax expense 7,900,592.86 87.66
IV. Net profit (Net loss is listed with
43,022,532.17 14,392,484.04
“-”)
V. Earnings per share -- --
i. Basic earnings per share
ii. Diluted earnings per share
24
国药集团一致药业股份有限公司 2014 年第三季度报告全文
VI. Other consolidated income
Inc: Other comprehensive items un-able
to re-classify as gains/losses in later
accounting period
Other comprehensive items
able to re-classify as gains/losses in
later accounting period while regulated
conditions are satisfy
VII. Total comprehensive income 43,022,532.17 14,392,484.04
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
5. Consolidated profit statement (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
Item Amount in this period Amount in last period
I. Total operating income 17,894,606,405.81 15,676,355,126.17
Including: Operating income 17,894,606,405.81 15,676,355,126.17
Interest income
Insurance gained
Commission charge and commission
income
II. Total operating cost 17,322,455,843.61 15,208,026,096.92
Including: Operating cost 16,460,036,038.82 14,381,122,227.18
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of compensation
Net amount of withdrawal of insurance
contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Operating tax and extras 36,859,658.29 32,966,662.80
Sales expenses 383,388,181.09 353,398,338.86
Administration expenses 330,858,718.45 303,141,697.44
Financial expenses 102,392,485.33 119,635,650.08
Losses of devaluation of asset 8,920,761.63 17,761,520.56
25
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed with
36,739,722.01 30,515,319.09
“-”)
Including: Investment income on
36,739,722.01 30,515,319.09
affiliated company and joint venture
Exchange income (Loss is listed with
“-”)
III. Operating profit (Loss is listed
608,890,284.21 498,844,348.34
with “-”)
Add: Non-operating income 36,864,548.07 29,276,636.55
Less: Non-operating expense 1,538,460.84 22,274,449.46
Including: Disposal loss of non-current
280,069.64 156,912.97
asset
IV. Total Profit (Loss is listed with
644,216,371.44 505,846,535.43
“-”)
Less: Income tax expense 125,875,954.02 98,584,630.53
V. Net profit (Net loss is listed with “-”) 518,340,417.42 407,261,904.90
Including: net profit realized before
consolidation by mergered party
Net profit attributable to owner’s of
505,688,779.43 396,685,115.71
parent company
Minority shareholders’ gains and losses 12,651,637.99 10,576,789.19
VI. Earnings per share -- --
i. Basic earnings per share 1.497 1.377
ii. Diluted earnings per share 1.497 1.377
VII. Other consolidated income -2,716,500.00
Inc: Other comprehensive items un-able
to re-classify as gains/losses in later -2,716,500.00
accounting period
Other comprehensive items
able to re-classify as gains/losses in
later accounting period while regulated
conditions are satisfy
VIII. Total comprehensive income 515,623,917.42 407,261,904.90
Total consolidated income attributable
503,001,311.93 396,685,115.71
to owners of parent company
Total consolidated income attributable
12,622,605.49 10,576,789.19
to minority shareholders
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
6. Profit Statement of parent company (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
26
国药集团一致药业股份有限公司 2014 年第三季度报告全文
In RMB
Items Amount in this period Amount in last period
I. Operating income 2,078,854,464.72 1,871,200,691.97
Less: operating cost 1,996,348,869.75 1,789,158,702.46
Operating tax and extras 6,249,456.18 3,500,049.67
Sales expenses 35,760,799.33 35,538,629.68
Administration expenses 36,834,667.09 35,407,135.00
Financial expenses -61,166,675.03 6,025,727.14
Losses of devaluation of asset 270,135.10 251,017.39
Add: Changing income of fair
value(Loss is listed with “-”)
Investment income (Loss is listed with
498,608,841.32 420,352,640.45
“-”)
Including: Investment income on
36,739,722.01 30,515,319.09
affiliated company and joint venture
II. Operating profit (Loss is listed
563,166,053.62 421,672,071.08
with “-”)
Add: Non-operating income 715,297.08 7,943,421.62
Less: Non-operating expense 0.08 2,050.00
Including: Disposal loss of non-current
asset
III. Total Profit (Loss is listed with
563,881,350.62 429,613,442.70
“-”)
Less: Income tax expense 16,251,065.83 -53,305.02
IV. Net profit (Net loss is listed with
547,630,284.79 429,666,747.72
“-”)
V. Earnings per share -- --
i. Basic earnings per share
ii. Diluted earnings per share
VI. Other consolidated income
-270,750.00
Inc: Other comprehensive items un-able
to re-classify as gains/losses in later
-270,750.00
accounting period
Other comprehensive items
able to re-classify as gains/losses in
later accounting period while regulated
conditions are satisfy
VII. Total comprehensive income 547,359,534.79 429,666,747.72
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
7. Consolidated Cash Flow Statement (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
27
国药集团一致药业股份有限公司 2014 年第三季度报告全文
In RMB
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling commodities
17,908,007,328.48 15,759,715,499.06
and providing labor services
Net increase of customer deposit and
interbank deposit
Net increase of loan from central bank
Net increase of capital borrowed from
other financial institution
Cash received from original insurance
contract fee
Net cash received from reinsurance
business
Net increase of insured savings and
investment
Net increase of disposal of transaction
financial asset
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Write-back of tax received 8,947,070.73 8,242,898.04
Other cash received concerning
75,769,060.23 53,709,097.32
operating activities
Subtotal of cash inflow arising from
17,992,723,459.44 15,821,667,494.42
operating activities
Cash paid for purchasing commodities
17,447,751,970.38 14,595,729,806.54
and receiving labor service
Net increase of customer loans and
advances
Net increase of deposits in central bank
and interbank
Cash paid for original insurance
contract compensation
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee slip
Cash paid to/for staff and workers 439,907,204.26 382,463,113.16
Taxes paid 421,428,798.02 349,077,917.15
Other cash paid concerning operating
272,979,736.89 249,583,919.13
activities
Subtotal of cash outflow arising from
18,582,067,709.55 15,576,854,755.98
operating activities
Net cash flows arising from operating
-589,344,250.11 244,812,738.44
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from investment income 28,152,000.00 28,152,000.00
Net cash received from disposal of
fixed, intangible and other long-term 1,257,052.51 3,028,761.00
assets
Net cash received from disposal of
28
国药集团一致药业股份有限公司 2014 年第三季度报告全文
subsidiaries and other units
Other cash received concerning
investing activities
Subtotal of cash inflow from investing
29,409,052.51 31,180,761.00
activities
Cash paid for purchasing fixed,
236,730,564.01 73,342,076.03
intangible and other long-term assets
Cash paid for investment
Net increase of mortgaged loans
Net cash received from subsidiaries and
1,644,172.91 151,731.71
other units
Other cash paid concerning investing
activities
Subtotal of cash outflow from investing
238,374,736.92 73,493,807.74
activities
Net cash flows arising from investing
-208,965,684.41 -42,313,046.74
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,930,265,413.47
investment
Including: Cash received from
absorbing minority shareholders’
investment by subsidiaries
Cash received from loans 174,372,388.34 598,850,496.45
Cash received from issuing bonds
Other cash received concerning
32,152,750.15 400,000,000.00
financing activities
Subtotal of cash inflow from financing
2,136,790,551.96 998,850,496.45
activities
Cash paid for settling debts 1,123,753,511.67 674,228,825.54
Cash paid for dividend and profit
183,572,083.63 176,840,535.37
distributing or interest paying
Including: Dividend and profit of
minority shareholder paid by 5,825,783.82 4,966,654.86
subsidiaries
Other cash paid concerning financing
50,827,980.27 414,085,233.92
activities
Subtotal of cash outflow from financing
1,358,153,575.57 1,265,154,594.83
activities
Net cash flows arising from financing
778,636,976.39 -266,304,098.38
activities
IV. Influence on cash and cash
equivalents due to fluctuation in 5,838.21 -6,572.26
exchange rate
V. Net increase of cash and cash
-19,667,119.92 -63,810,978.94
equivalents
Add: Balance of cash and cash
1,097,948,354.45 920,748,043.53
equivalents at the period -begin
VI. Balance of cash and cash
1,078,281,234.53 856,937,064.59
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
8. Cash Flow Statement of parent company (from year-begin to end of this period)
Prepared by China National Accord Medicines Corporation Ltd.
In RMB
29
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Item Amount in this period Amount in last period
I. Cash flows arising from operating
activities:
Cash received from selling commodities
2,178,553,762.47 1,915,280,492.82
and providing labor services
Write-back of tax received 0.00
Other cash received concerning
16,271,321.78 16,077,640.47
operating activities
Subtotal of cash inflow arising from
2,194,825,084.25 1,931,358,133.29
operating activities
Cash paid for purchasing commodities
2,155,142,728.62 1,893,911,070.75
and receiving labor service
Cash paid to/for staff and workers 39,046,375.47 38,651,909.44
Taxes paid 26,377,550.12 12,077,871.06
Other cash paid concerning operating
21,802,894.06 26,730,502.96
activities
Subtotal of cash outflow arising from
2,242,369,548.27 1,971,371,354.21
operating activities
Net cash flows arising from operating
-47,544,464.02 -40,013,220.92
activities
II. Cash flows arising from investing
activities:
Cash received from recovering
0.00
investment
Cash received from investment income 234,399,564.16 138,763,600.61
Net cash received from disposal of
fixed, intangible and other long-term 700.00 65,000.00
assets
Net cash received from disposal of
0.00
subsidiaries and other units
Other cash received concerning
2,954,312,357.21 1,490,052,164.08
investing activities
Subtotal of cash inflow from investing
3,188,712,621.37 1,628,880,764.69
activities
Cash paid for purchasing fixed,
166,131,758.87 13,653,720.05
intangible and other long-term assets
Cash paid for investment 8,110,000.00 100,000,000.00
Net cash received from subsidiaries and
6,761,000.00 151,731.71
other units
Other cash paid concerning investing
4,008,433,743.73 1,459,100,000.00
activities
Subtotal of cash outflow from investing
4,189,436,502.60 1,572,905,451.76
activities
Net cash flows arising from investing
-1,000,723,881.23 55,975,312.93
activities
III. Cash flows arising from financing
activities
Cash received from absorbing
1,930,265,413.47
investment
Cash received from loans 58,095,448.00 440,000,000.00
Cash received from issuing bonds
Other cash received concerning
394,669,491.62 1,265,475,600.48
financing activities
Subtotal of cash inflow from financing
2,383,030,353.09 1,705,475,600.48
activities
Cash paid for settling debts 945,000,000.00 322,000,000.00
30
国药集团一致药业股份有限公司 2014 年第三季度报告全文
Cash paid for dividend and profit
88,630,556.66 103,003,578.81
distributing or interest paying
Other cash paid concerning financing
128,579,308.55 1,270,743,410.18
activities
Subtotal of cash outflow from financing
1,162,209,865.21 1,695,746,988.99
activities
Net cash flows arising from financing
1,220,820,487.88 9,728,611.49
activities
IV. Influence on cash and cash
equivalents due to fluctuation in 1,201.00
exchange rate
V. Net increase of cash and cash
172,553,343.63 25,690,703.50
equivalents
Add: Balance of cash and cash
218,342,947.03 160,633,355.13
equivalents at the period -begin
VI. Balance of cash and cash
390,896,290.66 186,324,058.63
equivalents at the period -end
Legal representative: Yan Zhigang
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Zhou Feifei
II. Audit report
Whether the third quarter report was audited or not
□Yes √No
The third quarter report of the Company has not been audited
31
